Cargando…
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
BACKGROUND: Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of synergy between paclitaxel and cixutumumab, a monoc...
Autores principales: | Stockton, Shannon, Catalano, Paul, Cohen, Steven J, Burtness, Barbara A, Mitchell, Edith P, Dotan, Efrat, Lubner, Sam J, Kumar, Pankaj, Mulcahy, Mary F, Fisher, George A, Crandall, Theodore L, Benson, Al |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485278/ https://www.ncbi.nlm.nih.gov/pubmed/37104870 http://dx.doi.org/10.1093/oncolo/oyad096 |
Ejemplares similares
-
Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up
por: Rosenberg, Ari Joseph, et al.
Publicado: (2019) -
E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018) -
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021) -
ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
por: Cmelak, Anthony, et al.
Publicado: (2020) -
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)